ArticleAnimal bioscience2025
Serotonin promotes calcium accumulation and inhibits lipid accumulation in cultured goat mammary epithelial cells through HTR2A.
Article in Animal bioscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveFatty acids and calcium are both important nutrients in goat milk. Investigating the upstream molecular regulatory mechanisms that control the synthesis of milk fat and milk calcium in the mammary gland can help improve the quality of milk at its source. The objective of this study was to investigate the effects and regulatory pathways of serotonin (5-hydroxytryptamine, 5-HT) and its receptors on lipid synthesis and calcium ion levels in goat mammary epithelial cells (GMECs).
methodsGMECs isolated from live goats were treated with serotonin, overexpression of Serotonin receptor 2A (HTR2A), Sarpogrelate ([SAR] the specific antagonist of HTR2A), or a combination of these agents. The expression of genes related to de novo lipid synthesis in GMECs were detected using the Quantitative Real-Time polymerase chain reaction, the content of lipid droplets was detected using the BODIPY assay, and the calcium content was detected using the calcium chelating probe Fluo-3AM assay.
results5-HT dose-dependently promotes the activity of GEMCs, significantly inhibits the mRNA expression of key genes involved in de novo lipid synthesis such as ACC, FASN, SREBP1, SCD1 and ELOVL6 at a concentration of 100 μM, reduces triglyceride and total cholesterol content, suppresses lipid droplet accumulation in cells, and simultaneously promotes calcium accumulation in cells. Furthermore, overexpression of HTR2A in GMECs also induces an increase in cellular calcium levels and inhibits lipid synthesis and accumulation in cells. However, treatment of cells with SAR, the specific antagonist of HTR2A, significantly increases the levels of triglycerides, total cholesterol, and lipid droplet accumulation in cells.
conclusion5-HT inhibits lipid synthesis in GMECs while promoting an increase in cellular calcium levels, and this effect is mediated by the HTR2A receptor. Furthermorey, antagonists targeting HTR2A can reverse the inhibition of lipid synthesis and accumulation in cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.